The case described the issues faced by a mid-sized Indian generic pharmaceutical firm, in its attempt to acquire a small unlisted Japanese generics manufacturer. It showcases the strong motivation of a successful emerging market pharmaceutical firm to expand into the developed market, buoyed by its cost competitiveness. The case presents an opportunity to discuss the trade-offs involved with most of the dynamic decisions in a cross-border acquisition, such as estimation of synergies and value, bidding, and financing the acquisition. The case may be used in programmes on valuation, and mergers and acquisitions.
The authors thank Lupin’s senior management for the valuable information shared about the case context and for their comments on the case draft.
CitationDownload as .RIS
Indian Institute of Management Ahmedabad
Copyright © 2012 by the Indian Institute of Management, Ahmedabad